{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:18:16Z","timestamp":1788347896364,"version":"build-2803163510"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00103-017-2661-3","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T13:56:30Z","timestamp":1514382990000},"page":"116-128","source":"Crossref","is-referenced-by-count":1,"title":["Humanes Cytomegalievirus (HCMV)"],"prefix":"10.1007","volume":"61","member":"297","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"2661_CR1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00103-007-0194-x","volume":"50","author":"K Hambrecht","year":"2007","unstructured":"Hambrecht K, Jahn G (2007) Humanes Cytomegalovirus und kongenitale Infektion. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 50:1379\u20131392","journal-title":"Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz"},{"key":"2661_CR2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/JVI.73.2.878-886.1999","volume":"73","author":"M Klein","year":"1999","unstructured":"Klein M, Schoppel K, Amvrossiadis N, Mach M (1999) Strain-specific neutralization of human cytomegalovirus isolates by human sera. J\u00a0Virol 73:878\u2013886","journal-title":"J Virol"},{"key":"2661_CR3","volume-title":"Virology. 6th edition","year":"2013","unstructured":"Fields BN, Knipe DM, Howley PM (Hrsg) (2013) Virology. 6th edition. Wolters Kluwer Health\/Lippincott Williams & Wilkins, Philadelphia"},{"key":"2661_CR4","volume-title":"Principles and practice of infectious diseases. 7th edition","author":"GL Mandell","year":"2010","unstructured":"Mandell GL, Bennett JE, Dolin R (2010) Principles and practice of infectious diseases. 7th edition. Churchill Livingstone\/Elsevier, Philadelphia"},{"key":"2661_CR5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0166-3542(96)01006-6","volume":"32","author":"JTM Meer Van der","year":"1996","unstructured":"Van der Meer JTM, Drew WL, Bowden RA et al (1996) Summary of the international consensus symposium on advances in the diagnosis, treatment and prophylaxis of cytomegalovirus infection. Antiviral Res 32:119\u2013140","journal-title":"Antiviral Res"},{"key":"2661_CR6","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.imbio.2013.01.002","volume":"218","author":"O Fornara","year":"2013","unstructured":"Fornara O, Odeberg J, Khan Z et al (2013) Human cytomegalovirus particles directly suppress CD4 T-lymphocyte activation and proliferation. Immunobiol 218:1034\u20131040","journal-title":"Immunobiol"},{"key":"2661_CR7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0166-3542(98)00044-8","volume":"39","author":"MD Jong De","year":"1998","unstructured":"De Jong MD, Galasso GJ, Gazzard B et al (1998) Summary of the II. international symposium on cytomegalovirus. Antiviral Res 39:141\u2013162","journal-title":"Antiviral Res"},{"key":"2661_CR8","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2009.02824.x","volume":"9","author":"RB Freemann Jr","year":"2009","unstructured":"Freemann RB Jr (2009) The \u2018indirect\u2019 effects of cytomegalovirus infection. Am J Transpl 9:2453\u20132458","journal-title":"Am J Transpl"},{"key":"2661_CR9","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/trf.12074","volume":"53","author":"M Ziemann","year":"2013","unstructured":"Ziemann M, Juhl D, G\u00f6rg S, Hennig H (2013) The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk-patients. Transfusion 53:2183\u20132187","journal-title":"Transfusion"},{"key":"2661_CR10","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJM199806113382407","volume":"338","author":"JA Fishman","year":"1998","unstructured":"Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N\u00a0Engl J Med 338:1741\u20131751","journal-title":"N Engl J Med"},{"key":"2661_CR11","volume-title":"Clinical Practice of Transfusion Medicine. Third Edition","year":"1996","unstructured":"Petz LD, Swisher SN (Hrsg) (1996) Clinical Practice of Transfusion Medicine. Third Edition. Churchill Livingstone, New York"},{"key":"2661_CR12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1099\/0022-1317-72-9-2059","volume":"72","author":"J Taylor-Wiedeman","year":"1991","unstructured":"Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH (1991) Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J\u00a0Gen Virol 72:2059\u20132064","journal-title":"J Gen Virol"},{"key":"2661_CR13","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood.V88.4.1277.bloodjournal8841277","volume":"88","author":"M Movassagh","year":"1996","unstructured":"Movassagh M, Gozlan J, Senechal B, Baillou C, Petit JC, Lemoine FM (1996) Direct infection of CD34+ progenitor cells by human cytomegalovirus: Evidence for inhibition of hematopoiesis and viral replication. Blood 88:1277\u20131283","journal-title":"Blood"},{"key":"2661_CR14","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1182\/blood.V90.6.2482","volume":"90","author":"T Zhuravskaya","year":"1997","unstructured":"Zhuravskaya T, Maciejewski JP, Netski DM, Bruening E, Mackintosh FR, Jeor StS (1997) Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency. Blood 90:2482\u20132491","journal-title":"Blood"},{"key":"2661_CR15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00007890-199802150-00021","volume":"65","author":"S Larsson","year":"1998","unstructured":"Larsson S, Soderberg-Naucler C, Moller E (1998) Productive cytomegalovirus (CMV) infection exclusively in CD13-positive peripheral blood mononuclear cells from CMV-infected individuals: implications for prevention of CMV transmission. Transplantation 65:411\u2013415","journal-title":"Transplantation"},{"key":"2661_CR16","first-page":"26","volume":"21","author":"JD Roback","year":"2007","unstructured":"Roback JD, Su L, Zimring JC, Hillyer CD (2007) Transfusion-transmitted cytomegalovirus: Lessons from a murine model. Transf. Med Rev 21:26\u201336","journal-title":"Med Rev"},{"key":"2661_CR17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood.V93.1.394","volume":"93","author":"CA Bolovan-Fritts","year":"1999","unstructured":"Bolovan-Fritts CA, Mocarski ES, Wiedemann JA (1999) Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 93:394\u2013398","journal-title":"Blood"},{"key":"2661_CR18","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/JCM.43.3.1318-1324.2005","volume":"43","author":"J Meier","year":"2005","unstructured":"Meier J, Lienicke U, Tschirch E, Kr\u00fcger DH, Wauer RR, Pr\u00f6sch S (2005) Human cytomegalovirus reactivation during lactation and mother-to-child transmission in preterm infants. J\u00a0Clin Microbiol 43:1318\u20131324","journal-title":"J Clin Microbiol"},{"key":"2661_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1440-1754.2001.00645.x","volume":"37","author":"DE Trincado","year":"2001","unstructured":"Trincado DE, Rawlinson WD (2001) Congenital and perinatal infections with cytomegalovirus. J\u00a0Paed Child Health 37:187\u2013192","journal-title":"J Paed Child Health"},{"key":"2661_CR20","doi-asserted-by":"crossref","first-page":"e1937","DOI":"10.1542\/peds.2013-0076","volume":"131","author":"TM Lanzieri","year":"2013","unstructured":"Lanzieri TM, Dollard SC, Josephson CD, Schmid DS, Bialek SK (2013) Breast milk-acquired cytomegalovirus infection and disease in VLBW and premature infants. Pediatrics 131:e1937\u20131945","journal-title":"Pediatrics"},{"key":"2661_CR21","first-page":"F288","volume":"91","author":"J Maschmann","year":"2006","unstructured":"Maschmann J, Hamprecht K, Weissbrich B, Dietz K, Jahn G, Speer CP (2006) Freeze-thawing of breast milk does not prevent cytomegalovirus transmission to a preterm infant. Arch. Dis Child Fetal Neonatal. Ed 91:F288\u2013290","journal-title":"Ed"},{"key":"2661_CR22","first-page":"276","volume":"26","author":"CH Lee","year":"2007","unstructured":"Lee CH, Enright A, Benitz WE, Madan A (2007) Postnatal cytomegalovirus infection from frozen breast milk in preterm, low birth weight infants. Ped Infect Dis\u00a0J 26:276\u2013277","journal-title":"Ped Infect Dis J"},{"key":"2661_CR23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1203\/01.PDR.0000143155.84802.A3","volume":"56","author":"M Forsgren","year":"2004","unstructured":"Forsgren M (2004) Cytomegalovirus in breast milk: Reassessment of pasteurization and freeze-thawing. Pediatr Res 56:526\u2013528","journal-title":"Pediatr Res"},{"key":"2661_CR24","first-page":"71","volume":"84","author":"R Stocchi","year":"1999","unstructured":"Stocchi R, Ward KN, Fanin R, Baccarani M, Apperley JF (1999) Management of human cytomegalovirus infection and disease after allogenenic bone marrow transplantation. Haematologica 84:71\u201379","journal-title":"Haematologica"},{"key":"2661_CR25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0885066613476454","volume":"29","author":"G Travi","year":"2013","unstructured":"Travi G, Pergam SA (2013) Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J\u00a0Intensive Care Med 29:200\u2013212","journal-title":"J Intensive Care Med"},{"key":"2661_CR26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1592\/phco.30.2.144","volume":"30","author":"RJ Stratta","year":"2010","unstructured":"Stratta RJ, Pietrangeli C, Baillie GM (2010) Defining the risks for cytomegalovirus infection disease after solid organ transplantation. Pharmacotherapy 30:144\u2013157","journal-title":"Pharmacotherapy"},{"key":"2661_CR27","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0140-6736(96)11431-8","volume":"349","author":"MA Jacobson","year":"1997","unstructured":"Jacobson MA, Zegans M, Pavan PR et al (1997) Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349:1443\u20131445","journal-title":"Lancet"},{"key":"2661_CR28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/ajcp\/106.2.163","volume":"106","author":"D Przepiorka","year":"1996","unstructured":"Przepiorka D, LeParc GF, Werch J, Lichtiger B (1996) Prevention of transfusion-associated cytomegalovirus infection. Am J Clin Pathol 106:163\u2013169","journal-title":"Am J Clin Pathol"},{"key":"2661_CR29","first-page":"103","volume":"49","author":"U Krech","year":"1973","unstructured":"Krech U (1973) Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ 49:103\u2013106","journal-title":"Bull World Health Organ"},{"key":"2661_CR30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1537-2995.1992.32392213798.x","volume":"32","author":"HV Lamberson","year":"1992","unstructured":"Lamberson HV, Dock NL (1992) Prevention of transfusion-transmitted cytomegalovirus infection. Transfusion 32:196\u2013198","journal-title":"Transfusion"},{"key":"2661_CR31","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/trf.12390","volume":"53","author":"Y Furui","year":"2013","unstructured":"Furui Y, Satake M, Hoshi Y, Uchida S, Suzuki K, Tadokoro K (2013) Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Transfusion 53:2190\u20132197","journal-title":"Transfusion"},{"key":"2661_CR32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/OLQ.0b013e3181644b70","volume":"35","author":"SAS Staras","year":"2008","unstructured":"Staras SAS, Flander WD, Dollard SC, Pass RF, McGowan JE, Cannon MJ (2008) Influence of sexual activity on cytomegalovirus seroprevalence in the United States, 1988 \u2013 1994. Sex Transm Dis 35:472\u2013479","journal-title":"Sex Transm Dis"},{"key":"2661_CR33","volume-title":"Virusdiagnostik. Diagnostische Bibliothek","author":"K Reimer","year":"1996","unstructured":"Reimer K, Meisel H (1996) Humanes Zytomegalievirus. In: Porstmann T (Hrsg) Virusdiagnostik. Diagnostische Bibliothek, Bd. 1. Blackwell Wissenschafts-Verlag, Berlin\/Wien"},{"key":"2661_CR34","volume-title":"Zytomegalievirus (CMV). In: Diagnostik und Therapie von Viruskrankheiten. Leitlinien der Gesellschaft f\u00fcr Virologie. M\u00fcnchen","year":"2004","unstructured":"Mertens T, Haller OA, Klenk HD (Hrsg) (2004) Zytomegalievirus (CMV). In: Diagnostik und Therapie von Viruskrankheiten. Leitlinien der Gesellschaft f\u00fcr Virologie. M\u00fcnchen. Urban & Fischer, Jena"},{"key":"2661_CR35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","volume":"96","author":"CN Kotton","year":"2013","unstructured":"Kotton CN, Kumar D, Caliendo AM et al (2013) Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:333\u2013360","journal-title":"Transplantation"},{"key":"2661_CR36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1600-6143.2004.00692.x","volume":"5","author":"JK Preiksaitis","year":"2005","unstructured":"Preiksaitis JK, Brennan DC, Fishman J, Allen U (2005) Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transpl 5:218\u2013227","journal-title":"Am J Transpl"},{"key":"2661_CR37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s10620-007-9834-0","volume":"53","author":"V Subramanian","year":"2008","unstructured":"Subramanian V (2008) Distinguishing primary CMV infection from reactivation of latent infection. Dig Dis Sci 53:140","journal-title":"Dig Dis Sci"},{"key":"2661_CR38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jcv.2007.10.015","volume":"41","author":"T Lazzarotto","year":"2008","unstructured":"Lazzarotto T, Guerra B, Lanari M, Gabrielli L, Landini MP (2008) New advances in the diagnosis of congenital cytomegalovirus infection. J\u00a0Clin Virol 41:192\u2013197","journal-title":"J Clin Virol"},{"key":"2661_CR39","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/eji.201243100","volume":"43","author":"M Ritter","year":"2013","unstructured":"Ritter M, Schmidt T, Dirks J et al (2013) Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol 43:1099\u20131108","journal-title":"Eur J Immunol"},{"key":"2661_CR40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","volume":"162","author":"VC Emery","year":"2013","unstructured":"Emery VC, Zuckerman M, Jackson G et al (2013) Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Brit J Haematol 162:25\u201339","journal-title":"Brit J Haematol"},{"key":"2661_CR41","volume-title":"Bedeutung der Zytomegalievirusinfektion in der Transfusionsmedizin. Inaugural-Dissertation","author":"G Bringmann","year":"1990","unstructured":"Bringmann G (1990) Bedeutung der Zytomegalievirusinfektion in der Transfusionsmedizin. Inaugural-Dissertation. Medizinische Fakult\u00e4t der Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf"},{"key":"2661_CR42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.0042-9007.2004.00388.x","volume":"86","author":"M Hecker","year":"2004","unstructured":"Hecker M, Qui D, Marquardt K, Bein G, Hackstein H (2004) Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang 86:41\u201344","journal-title":"Vox Sang"},{"key":"2661_CR43","first-page":"348","volume":"20","author":"A Kothari","year":"2002","unstructured":"Kothari A, Ramachandran VG, Gupta P, Singh B, Talwar V (2002) Seroprevalence of cytomegalovirus among voluntary blood donors in Dehli, India. J\u00a0Health Popul Nutr 20:348\u2013351","journal-title":"J Health Popul Nutr"},{"issue":"suppl 1","key":"2661_CR44","first-page":"32","volume":"21","author":"B Weber","year":"1994","unstructured":"Weber B, Doerr HW (1994) Diagnosis and epidemiology of transfusion-associated human cytomegalovirus infection: recent developments. Infusionsther Transfusionsmed 21(suppl 1):32\u201339","journal-title":"Infusionsther Transfusionsmed"},{"key":"2661_CR45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1423-0410.1993.tb02510.x","volume":"64","author":"G Galea","year":"1993","unstructured":"Galea G, Urbaniak SJ (1993) Cytomegalovirus studies on blood donors in north-east Scotland and a review of UK data. Vox Sang 64:24\u201330","journal-title":"Vox Sang"},{"key":"2661_CR46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00430-002-0148-8","volume":"191","author":"H Schennach","year":"2002","unstructured":"Schennach H, Hessenberger G, Mayersbach P, Sch\u00f6nitzer D, Fuchs D (2002) Acute cytomegalovirus infections in blood donors are indicated by increased serum neopterin concentrations. Med Microbiol Immunol 191:115\u2013118","journal-title":"Med Microbiol Immunol"},{"key":"2661_CR47","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/j.1537-2995.2007.01420.x","volume":"47","author":"M Ziemann","year":"2007","unstructured":"Ziemann M, Krueger S, Maier AB, Unmack A, Goerg S, Hennig H (2007) High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 47:1972\u20131983","journal-title":"Transfusion"},{"key":"2661_CR48","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/trf.12074","volume":"53","author":"M Ziemann","year":"2013","unstructured":"Ziemann M, Heuft HG, Frank K, Kraas S, G\u00f6rg S, Hennig H (2013) Window period duration during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion 53:1088\u20131094","journal-title":"Transfusion"},{"key":"2661_CR49","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1537-2995.2009.02486.x","volume":"50","author":"Y Wu","year":"2010","unstructured":"Wu Y, Zou S, Cable R et al (2010) Direct assessment of cytomegalovirus transfusion-transmitted risk after universal leucoreduction. Transfusion 50:776\u2013786","journal-title":"Transfusion"},{"key":"2661_CR50","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1537-2995.2011.03203.x","volume":"51","author":"T Thiele","year":"2011","unstructured":"Thiele T, Kr\u00fcger W, Zimmermann K et al (2011) Transmission of cytomegalovirus (CMV) infection by leucoreduced blood products not tested for CMV antibodies: A single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation. Transfusion 51:2620\u20132626","journal-title":"Transfusion"},{"key":"2661_CR51","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1111\/j.1537-2995.2012.03739.x","volume":"52","author":"T Nash","year":"2012","unstructured":"Nash T, Hoffmann S, Butch S, Davenport R, Cooling L (2012) Safety of leucoreduced cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant patients. Transfusion 52:2270\u20132272","journal-title":"Transfusion"},{"key":"2661_CR52","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.bbmt.2013.09.013","volume":"19","author":"N Kekre","year":"2013","unstructured":"Kekre N, Tokessy M, Mallick R et al (2013) Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leucoreduction? Biol Blood Marr Transpl 19:1719\u20131724","journal-title":"Biol Blood Marr Transpl"},{"key":"2661_CR53","unstructured":"Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (H\u00e4motherapie) vom 4. Mai 2010. Bundesanzeiger Nr.\u00a0101a vom 9. Juli 2010"},{"key":"2661_CR54","unstructured":"Querschnitts-Leitlinien (B\u00c4K) zur Therapie mit Blutkomponenten und Plasmaderivaten (2014) http:\/\/www.bundesaerztekammer.de\/downloads\/QLL_Haemotherapie_2014.pdf . Zugegriffen 31. Juli 2017"},{"key":"2661_CR55","unstructured":"SaBTO Position Statement: Cytomegalovirus tested blood components. 2012 https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/215125\/dh_133086.pdf Zugegriffen 31. Juli 2017"},{"key":"2661_CR56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1099-1654(199709)7:3<181::AID-RMV200>3.0.CO;2-W","volume":"7","author":"SR Riddell","year":"1997","unstructured":"Riddell SR, Greenberg PD (1997) T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev Med Virol 7:181\u2013192","journal-title":"Rev Med Virol"},{"key":"2661_CR57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.cji.0000184472.28832.d3","volume":"29","author":"GA Bosch van den","year":"2006","unstructured":"van den Bosch GA, Ponsaerts P, Vanham G, van Bockstaele DR, Berneman ZN, van Tendeloo VF (2006) Cellular immunotherapy for cytomegalovirus and HIV-1 infection. J\u00a0Immunother 29:107\u2013121","journal-title":"J Immunother"},{"key":"2661_CR58","first-page":"9","volume":"5","author":"P Moss","year":"2005","unstructured":"Moss P, Rickinson A (2005) Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev 5:9\u201320","journal-title":"Nat Rev"},{"key":"2661_CR59","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1586\/erv.13.46","volume":"12","author":"V Dasari","year":"2013","unstructured":"Dasari V, Smith C, Khanna R (2013) Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases. Expert Rev Vaccines 12:661\u2013676","journal-title":"Expert Rev Vaccines"},{"key":"2661_CR60","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJMoa043337","volume":"353","author":"G Nigro","year":"2005","unstructured":"Nigro G, Adler SP, La Torre R, Best AM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N\u00a0Engl J Med 353:1350\u20131362","journal-title":"N Engl J Med"},{"key":"2661_CR61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-2007-984409","volume":"24","author":"M Aslam","year":"2007","unstructured":"Aslam M, Anderson JL, Guglietti D, Cardwell D (2007) CMV-induced neonatal thrombocytopenia: a case report and review of the literature. Am J Perinat 24:429\u2013434","journal-title":"Am J Perinat"},{"key":"2661_CR62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-0012.2007.00750.x","volume":"22","author":"N Bonaros","year":"2007","unstructured":"Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A (2007) CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 22:89\u201397","journal-title":"Clin Transplant"},{"key":"2661_CR63","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-3148.1999.00193.x","volume":"9","author":"DH Pamphilon","year":"1999","unstructured":"Pamphilon DH, Rider JR, Barbara JA, Williamson LM (1999) Prevention of transfusion-transmitted cytomegalovirus infection. Transfus Med 9:115\u2013123","journal-title":"Transfus Med"},{"key":"2661_CR64","volume-title":"Transfusionsmedizin","year":"2010","unstructured":"M\u00fcller-Eckhardt C, Kiefel V (Hrsg) (2010) Transfusionsmedizin, 4.\u00a0Aufl. Springer, Berlin","edition":"4"},{"key":"2661_CR65","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/00007890-199811270-00012","volume":"66","author":"P Ljungman","year":"1998","unstructured":"Ljungman P, Aschan J, Lewensohn-Fuchs I et al (1998) Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 66:1330\u20131334","journal-title":"Transplantation"},{"key":"2661_CR66","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000150568","volume":"40","author":"JU Vogel","year":"1997","unstructured":"Vogel JU, Scholz M, Cinatl J Jr (1997) Treatment of cytomegalovirus diseases. Intervirology 40:357\u2013367","journal-title":"Intervirology"},{"key":"2661_CR67","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM199904223401608","volume":"340","author":"HH Balfour","year":"1999","unstructured":"Balfour HH (1999) Antiviral Drugs. N\u00a0Engl J Med 340:1255\u20131268","journal-title":"N Engl J Med"},{"key":"2661_CR68","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","volume":"112","author":"KP Micklethwaite","year":"2008","unstructured":"Micklethwaite KP, Clancy L, Sandher U et al (2008) Prophylactic infusion of cytomegalovirus specific cytotoxic T-lymphocytes stimulated with Ad5f35pp65 gene modified dendritic cells following allogenic haemopoietic stem cell transplantation. Blood 112:3974\u20133981","journal-title":"Blood"},{"key":"2661_CR69","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(05)66553-1","volume":"365","author":"EM Hodson","year":"2005","unstructured":"Hodson EM, Jones CA, Webster AC et al (2005) Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365:2105\u20132115","journal-title":"Lancet"},{"key":"2661_CR70","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.transproceed.2007.07.074","volume":"39","author":"MAM Diaz","year":"2007","unstructured":"Diaz MAM, Romero NC, S\u00e1nchez-Fructuoso A et al (2007) Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled study. Transpl Proc 39:2231\u20132232","journal-title":"Transpl Proc"},{"key":"2661_CR71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2006.00618.x","volume":"21","author":"JA Fishman","year":"2007","unstructured":"Fishman JA, Emery V, Freeman R et al (2007) Cytomegalovirus in transplantation \u2013 challenging the status quo. Clin Transplant 21:149\u2013158","journal-title":"Clin Transplant"},{"key":"2661_CR72","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ctr.12138","volume":"27","author":"SM Fallatah","year":"2013","unstructured":"Fallatah SM, Marquez MA, Bazerbachi F et al (2013) Cytomegalovirus infection post-pancreas-kidney transplantation \u2013 results of antiviral prophylaxis in high-risk patients. Clin Transplant 27:503\u2013509","journal-title":"Clin Transplant"},{"key":"2661_CR73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/tid.12226","volume":"16","author":"Y Meije","year":"2014","unstructured":"Meije Y, Fort\u00fan J, Len \u00d3 et al (2014) Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+\/R-): experience from the RESITRA-REIPI cohort. Transpl Infect Dis 16:387\u2013396","journal-title":"Transpl Infect Dis"},{"key":"2661_CR74","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/ajt.12042","volume":"13","author":"C Cunha-Bang da","year":"2013","unstructured":"da Cunha-Bang C, Kirkby N, S\u00d8nderholm M et al (2013) The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. Am J Transpl 13:458\u2013466","journal-title":"Am J Transpl"},{"key":"2661_CR75","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcv.2013.04.004","volume":"57","author":"K Yeon Choi","year":"2013","unstructured":"Yeon Choi K, Sharon B, Balfour HH Jr, Belani K, Pozos TC, Schleiss MR (2013) Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection. J\u00a0Clin Virol 57:356\u2013360","journal-title":"J Clin Virol"},{"key":"2661_CR76","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.10.011","volume":"101","author":"TE Komatsu","year":"2014","unstructured":"Komatsu TE, Pikis A, Naeger LK, Harrington P (2014) Resistance of human cytomegalovirus to ganciclovir\/valganciclovir: a comprehensive review of putative resistance pathways. Antivir Res 101:12\u201325","journal-title":"Antivir Res"},{"key":"2661_CR77","first-page":"1101","volume":"122","author":"P Ljungman","year":"2013","unstructured":"Ljungman P (2013) CMV: a warrior against leukemia? Transplantation 122:1101\u20131102","journal-title":"Transplantation"},{"key":"2661_CR78","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","volume":"369","author":"FM Marty","year":"2013","unstructured":"Marty FM, Drew J, Winston DJ et al (2013) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N\u00a0Engl J Med 369:1227\u20131236","journal-title":"N Engl J Med"},{"key":"2661_CR79","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","volume":"370","author":"RF Chemaly","year":"2014","unstructured":"Chemaly RF, Ullmann AJ, Stoelben S et al (2014) Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N\u00a0Engl J Med 370:1781\u20131789","journal-title":"N Engl J Med"},{"key":"2661_CR80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","volume":"213","author":"P Lischka","year":"2016","unstructured":"Lischka P, Michel D, Zimmermann H (2016) Characterization of Cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of Letermovir (AIC246, MK8228). J\u00a0Infect Dis 213:23\u201330","journal-title":"J Infect Dis"},{"key":"2661_CR81","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12185-008-0051-1","volume":"87","author":"Y Asano-Mori","year":"2009","unstructured":"Asano-Mori Y, Kanda Y, Oshima K et al (2009) Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol 87:310\u2013318","journal-title":"Int J Hematol"},{"key":"2661_CR82","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","volume":"111","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Ravandi F, Riehl T et al (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111:1816\u20131819","journal-title":"Blood"},{"key":"2661_CR83","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11940-008-0020-2","volume":"10","author":"MR Schleiss","year":"2008","unstructured":"Schleiss MR (2008) Congenital cytomegalovirus infection: update on management strategies. Curr Treat Opt Neur 10:186\u2013192","journal-title":"Curr Treat Opt Neur"},{"key":"2661_CR84","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/petr.12118","volume":"17","author":"S Kowalsky","year":"2013","unstructured":"Kowalsky S, Arnon R, Posada R (2013) Prevention of cytomegalovirus following solid organ transplantation: A literature review. Ped Transpl 17:499\u2013509","journal-title":"Ped Transpl"},{"key":"2661_CR85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.molmed.2005.11.006","volume":"12","author":"R Khanna","year":"2006","unstructured":"Khanna R, Diamond DJ (2006) Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12:26\u201333","journal-title":"Trends Mol Med"},{"key":"2661_CR86","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1469-0691.2007.01781.x","volume":"13","author":"C Steininger","year":"2007","unstructured":"Steininger C (2007) Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Inf 13:953\u2013963","journal-title":"Clin Microbiol Inf"},{"key":"2661_CR87","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jcv.2007.11.008","volume":"41","author":"SP Adler","year":"2008","unstructured":"Adler SP (2008) Human CMV vaccine trials: what if CMV caused a rash? J\u00a0Clin Virol 41:231\u2013236","journal-title":"J Clin Virol"},{"key":"2661_CR88","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","volume":"12","author":"MA Kharfan-Dabja","year":"2012","unstructured":"Kharfan-Dabja MA, Boeckh M, Wilck MB et al (2012) A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomized, double blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12:290\u2013299","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"2661_CR89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1469-0691.12449","volume":"Suppl. 5","author":"F Rieder","year":"2014","unstructured":"Rieder F, Steininger C (2014) CMV vaccine: phase II clinical trial results. Clin Microbiol Inf Suppl. 5(20):95\u2013102","journal-title":"Clin Microbiol Inf"},{"key":"2661_CR90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.vaccine.2013.09.042","volume":"17","author":"PR Krause","year":"2013","unstructured":"Krause PR, Bialek SR, Boppana SB et al (2013) Priorities for CMV vaccine development. Vaccine 17:4\u201310","journal-title":"Vaccine"},{"key":"2661_CR91","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(03)14673-9","volume":"362","author":"H Einsele","year":"2003","unstructured":"Einsele H (2003) Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option? Lancet 362:1343\u20131344","journal-title":"Lancet"},{"key":"2661_CR92","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","volume":"99","author":"H Einsele","year":"2002","unstructured":"Einsele H, Roosnek E, Rufer N et al (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916\u20133922","journal-title":"Blood"},{"key":"2661_CR93","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.exphem.2005.12.018","volume":"34","author":"C Rosa La","year":"2006","unstructured":"La Rosa C, Wang Z, Lacey SF et al (2006) In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp Hematol 34:497\u2013507","journal-title":"Exp Hematol"},{"key":"2661_CR94","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/01.cji.0000211302.52503.93","volume":"29","author":"JJ Melenhorst","year":"2006","unstructured":"Melenhorst JJ, Solomon SR, Shenoy A et al (2006) Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J\u00a0Immunother 29:436\u2013443","journal-title":"J Immunother"},{"key":"2661_CR95","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/j.1537-2995.2007.01439.x","volume":"47","author":"A Paine","year":"2007","unstructured":"Paine A, Oelke M, Blasczyk R, Elz-Vesper B (2007) Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells. Transfusion 47:2143\u20132152","journal-title":"Transfusion"},{"key":"2661_CR96","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","volume":"13","author":"K Micklethwaite","year":"2007","unstructured":"Micklethwaite K, Hansen A, Foster A et al (2007) Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-Lymphocytes following allogenic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13:707\u2013714","journal-title":"Biol Blood Marrow Transplant"},{"key":"2661_CR97","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/CJI.0b013e31803b945b","volume":"30","author":"L Bao","year":"2007","unstructured":"Bao L, Sun Q, Lucas KG (2007) Rapid generation of CMV pp65-specific T cells for immunotherapy. J\u00a0Immunother 30:557\u2013561","journal-title":"J Immunother"},{"key":"2661_CR98","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood.V97.4.994","volume":"97","author":"K Peggs","year":"2001","unstructured":"Peggs K, Verfuerth S, Mackinnon S (2001) Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 97:994\u20131000","journal-title":"Blood"},{"key":"2661_CR99","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.V98.3.505","volume":"98","author":"S Szmania","year":"2001","unstructured":"Szmania S, Galloway A, Bruorton M et al (2001) Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 98:505\u2013512","journal-title":"Blood"},{"key":"2661_CR100","first-page":"379","volume":"202","author":"M Cobbold","year":"2005","unstructured":"Cobbold M, Khan N, Pourgheysari B et al (2005) Adoptive transfer of cytomegalovirus specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J\u00a0Engl Med 202:379\u2013386","journal-title":"J Engl Med"},{"key":"2661_CR101","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/asheducation-2006.1.486","volume":"2006","author":"JD Roback","year":"2006","unstructured":"Roback JD (2006) Vaccine-enhanced donor lymphocyte infusion (veDLI). Hematology 2006:486\u2013491","journal-title":"Hematology"},{"key":"2661_CR102","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1537-2995.2006.00773.x","volume":"46","author":"H Sakagawa","year":"2006","unstructured":"Sakagawa H, Azuma H, Fujihara M, Ikeda H (2006) Clinical-scale expansion of human cytomegalovirus-specific cytotoxic T lymphocytes from peripheral blood mononuclear cells requiring single-peptide stimulation and feeder cells but not additional antigen-presenting cells. Transfusion 46:516\u2013522","journal-title":"Transfusion"},{"key":"2661_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00410","author":"B Eiz-Vesper","year":"2013","unstructured":"Eiz-Vesper B, Maecker-Kolhoff, Blasczyk R (2013) Adoptive immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2012.00410","journal-title":"Front Immunol"},{"key":"2661_CR104","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcmd.2007.07.003","volume":"40","author":"S Mackinnon","year":"2008","unstructured":"Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M (2008) Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 40:63\u201367","journal-title":"Blood Cells Mol Dis"},{"key":"2661_CR105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bcmd.2007.07.002","volume":"40","author":"H Einsele","year":"2008","unstructured":"Einsele H, Kapp M, Grigoleit GU (2008) CMV-specific cell therapy. Blood Cells Mol Dis 40:71\u201375","journal-title":"Blood Cells Mol Dis"},{"key":"2661_CR106","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.bbmt.2013.01.021","volume":"19","author":"LE Clancy","year":"2013","unstructured":"Clancy LE, Blyth E, Simms RM et al (2013) Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution. Biol Blood Marrow Transplant 19:725\u2013734","journal-title":"Biol Blood Marrow Transplant"},{"key":"2661_CR107","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjh.12082","volume":"160","author":"ER Samuel","year":"2012","unstructured":"Samuel ER, Newton K, Mackinnon S, Lowdell MW (2012) Successful isolation and expansion of CMV-reactive T cells from G-CSF mobilized donors that retain a strong cytotoxic effector function. Brit J Haematol 160:87\u2013100","journal-title":"Brit J Haematol"},{"key":"2661_CR108","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2005-07-2746","volume":"107","author":"Y Chalandon","year":"2006","unstructured":"Chalandon Y, Degermann S, Villard J et al (2006) Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood 107:389\u2013396","journal-title":"Blood"},{"key":"2661_CR109","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","volume":"121","author":"E Blyth","year":"2013","unstructured":"Blyth E, Clancy L, Simms R et al (2013) Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogenic stem cell transplantation. Blood 121:3745\u20133758","journal-title":"Blood"},{"key":"2661_CR110","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/infdis\/153.3.478","volume":"153","author":"JD Meyers","year":"1986","unstructured":"Meyers JD, Flournoy N, Thomas ED (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J\u00a0Infect Dis 153:478\u2013488","journal-title":"J Infect Dis"},{"key":"2661_CR111","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/521896","volume":"45","author":"JS Cervia","year":"2007","unstructured":"Cervia JS, Wenz B, Ortolando GA (2007) Leukocyte reduction\u2019s role in the attenuation of infection risks among transfusion recipients. Clin Inf Dis 45:1008\u20131013","journal-title":"Clin Inf Dis"},{"key":"2661_CR112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0887-7963(99)80084-4","volume":"13","author":"CD Hillyer","year":"1999","unstructured":"Hillyer CD, Lankford KV, Roback JD, Gillespie TW, Silberstein LE (1999) Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. Transfus Med Rev 13:1\u201317","journal-title":"Transfus Med Rev"},{"key":"2661_CR113","first-page":"209","volume":"11","author":"H Rubie","year":"1993","unstructured":"Rubie H, Attal M, Campardou AM et al (1993) Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant 11:209\u2013214","journal-title":"Bone Marrow Transplant"},{"key":"2661_CR114","first-page":"1137","volume":"103","author":"MR Visconti","year":"2004","unstructured":"Visconti MR, Pennington J, Garner SF, Allain JP, Willamson LM (2004) Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real-time quantitative PCR. Transf Med 103:1137\u20131139","journal-title":"Transf Med"},{"key":"2661_CR115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1386-6532(98)00047-6","volume":"38","author":"W Lau","year":"1998","unstructured":"Lau W, Onizuka R, Krajden M (1998) Polymerase chain reaction based assessment of leukoreduction efficacy using a cytomegalovirus DNA transfected human T-cell line. J\u00a0Clin Virol 38:109\u2013116","journal-title":"J Clin Virol"},{"key":"2661_CR116","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/blood-2002-10-3143","volume":"101","author":"GW Nichols","year":"2003","unstructured":"Nichols GW, Price TH, Gooley T, Corey L, Boeckh M (2003) Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 101:4195\u20134200","journal-title":"Blood"},{"key":"2661_CR117","first-page":"195","volume":"20","author":"G Caspari","year":"2003","unstructured":"Caspari G, Cassens U, Hebart H, Kl\u00fcter H, Mansouri-Taleghani B, W\u00fcllenweber J (2003) Aktuelle Aspekte zur Vermeidung von transfusionsassoziierten CMV-\u00dcbertragungen. Stellungsnahme der Sektionen \u201eSicherheit in der H\u00e4motherapie\u201c und \u201eTransplantation und Zelltherapie\u201c der DGTI. Transfus Med Hemoth 20:195\u2013198","journal-title":"Transfus Med Hemoth"},{"key":"2661_CR118","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1046\/j.1365-2141.2002.03746.x","volume":"118","author":"MD Ronghe","year":"2002","unstructured":"Ronghe MD, Foot ABM, Cornish JM et al (2002) The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogenic stem cell transplantation. Br J Haematol 118:1124\u20131127","journal-title":"Br J Haematol"},{"key":"2661_CR119","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.tmrv.2005.02.002","volume":"19","author":"EC Vamvakas","year":"2005","unstructured":"Vamvakas EC (2005) Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion\u00a0? A review of the literature and meta-analysis. Transf Med Rev 19:181\u2013199","journal-title":"Transf Med Rev"},{"key":"2661_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13478","author":"M Mainou","year":"2016","unstructured":"Mainou M, Alahdab F, Tobian AAR et al (2016) Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis. Transfusion. https:\/\/doi.org\/10.1111\/trf.13478","journal-title":"Transfusion"},{"key":"2661_CR121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/vox.12250","volume":"109","author":"CR Seed","year":"2015","unstructured":"Seed CR, Wong J, Polizzotto MN, Faddy H, Keller AJ, Pink J (2015) The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components. Vox Sang 109:11\u201317","journal-title":"Vox Sang"},{"key":"2661_CR122","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/tme.12219","volume":"25","author":"S Hall","year":"2015","unstructured":"Hall S, Danby R, Osman H et al (2015) Transfusion in CMV seronegative T-depleted allogenic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a UK dual centre experience. Transf Med 25:418\u2013423","journal-title":"Transf Med"},{"key":"2661_CR123","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/infdis\/157.3.523","volume":"157","author":"JK Preiksaitis","year":"1988","unstructured":"Preiksaitis JK, Brown L, McKenzie M (1988) The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J\u00a0Infect Dis 157:523\u2013529","journal-title":"J Infect Dis"},{"key":"2661_CR124","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/rmv.353","volume":"12","author":"JD Roback","year":"2002","unstructured":"Roback JD (2002) CMV and blood transfusions. Rev Med Virol 12:211\u2013219","journal-title":"Rev Med Virol"},{"key":"2661_CR125","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1537-2995.1988.28689059044.x","volume":"28","author":"SP Adler","year":"1988","unstructured":"Adler SP (1988) Data that suggest that FFP does not transmit CMV. Transfusion 28:604","journal-title":"Transfusion"},{"key":"2661_CR126","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0934-8840(11)80802-9","volume":"282","author":"B Weber","year":"1995","unstructured":"Weber B, Rabenau H, Berger A et al (1995) Seroprevalence of HCV, HAV, HBV, HDV, CMV and HIV in high risk groups\/Frankfurt a. M., Germany. Zentralbl Bakteriol 282:102\u2013112","journal-title":"Zentralbl Bakteriol"},{"key":"2661_CR127","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.1993.tb08684.x","volume":"85","author":"M Sivakumaran","year":"1993","unstructured":"Sivakumaran M, Hutchinson RM, Wood JK, Revill JA, Ghosh K, Myint S (1993) Removal of cytomegalovirus (CMV) infected leucocytes from CMV seropositive blood units by bedside blood filtration. Br J Haematol 85:232\u2013234","journal-title":"Br J Haematol"},{"key":"2661_CR128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1537-2995.1998.38398222871.x","volume":"38","author":"S Larsson","year":"1998","unstructured":"Larsson S, Soderberg-Naucler C, Wang FZ, Moeller E (1998) Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion 38:271\u2013278","journal-title":"Transfusion"},{"key":"2661_CR129","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.1999.02926.x","volume":"141","author":"K Asadullah","year":"1999","unstructured":"Asadullah K, Proesch S, Audring H et al (1999) A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: An association with systemic tumour necrosis factor alpha overexpression. Br J Dermatol 141:94\u2013102","journal-title":"Br J Dermatol"},{"key":"2661_CR130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1537-2995.2003.00337.x","volume":"43","author":"WL Drew","year":"2003","unstructured":"Drew WL, Tegtmeier G, Alter HJ, Laycock ME, Miner RC, Busch MP (2003) Frequency and duration of plasma CMV virema in seroconverting blood donors and recipients. Transfusion 43:309\u2013313","journal-title":"Transfusion"},{"key":"2661_CR131","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1537-2995.2003.00312.x","volume":"43","author":"JD Roback","year":"2003","unstructured":"Roback JD, Drew WL, Laycock ME, Todd D, Hillyer CD, Bush MP (2003) CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion 43:314\u2013321","journal-title":"Transfusion"},{"key":"2661_CR132","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/314939","volume":"180","author":"F Zanghellini","year":"1999","unstructured":"Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF (1999) Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features. J\u00a0Inf Dis 180:702\u2013707","journal-title":"J Inf Dis"},{"key":"2661_CR133","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jcv.2005.09.020","volume":"35","author":"C Zhang","year":"2006","unstructured":"Zhang C, Buchanan H, Andrews W, Evans A, Pass RF (2006) Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and virus shedding. J\u00a0Clin Virol 35:338\u2013342","journal-title":"J Clin Virol"},{"key":"2661_CR134","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1017\/S0950268809990094","volume":"137","author":"KG Badami","year":"2009","unstructured":"Badami KG, McQuilkan-Bickerstaffe S, Wells JE, Parata M (2009) Cytomegalovirus seroprevalence and \u2018cytomegalovirus-safe\u201d seropositive blood donors. Epidemiol Infect 137:1776\u20131780","journal-title":"Epidemiol Infect"},{"key":"2661_CR135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000357102","volume":"41","author":"M Ziemann","year":"2014","unstructured":"Ziemann M, Hennig H (2014) Prevention of transfusion-transmitted cytomegalovirus infections: Which is the optimal strategy? Transfus Med Hemoth 41:40\u201344","journal-title":"Transfus Med Hemoth"},{"key":"2661_CR136","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/cid\/cis900","volume":"56","author":"HH Hirsch","year":"2013","unstructured":"Hirsch HH, Lautenschlager I, Pinsky BA et al (2013) An international multicenter performance analysis of cytomegalovirus load tests. Clin Inf Dis 56:367\u2013373","journal-title":"Clin Inf Dis"},{"key":"2661_CR137","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.diagmicrobio.2013.01.014","volume":"75","author":"BS Pritt","year":"2013","unstructured":"Pritt BS, Germer JJ, Gomez-Urena E et al (2013) Conversion to the COBAS AmpliPrep\/COBAS TaqMan CMV test for management of CMV disease in transplant recipients. Diagn Microbol Inf Dis 75:440\u2013442","journal-title":"Diagn Microbol Inf Dis"},{"key":"2661_CR138","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1128\/JCM.00067-13","volume":"51","author":"N Schnepf","year":"2013","unstructured":"Schnepf N, Scieux C, Resche-Riggon M et al (2013) Fully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott realtime CMV assay in the era of the CMV international standard. J\u00a0Clin Microbiol 51:2096\u20132102","journal-title":"J Clin Microbiol"},{"key":"2661_CR139","first-page":"227","volume":"7","author":"WJ Miller","year":"1991","unstructured":"Miller WJ, McCullough J, Balfour HH Jr et al (1991) Prevention of cytomegalovirus infection following bone marrow transplantation: A randomized trial of blood product screening. Bone Marrow Transplant 7:227\u2013234","journal-title":"Bone Marrow Transplant"},{"key":"2661_CR140","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598","volume":"86","author":"RA Bowden","year":"1995","unstructured":"Bowden RA, Slichter SJ, Sayers M et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598\u20133603","journal-title":"Blood"},{"key":"2661_CR141","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.bmt.1701361","volume":"22","author":"AB Narvios","year":"1998","unstructured":"Narvios AB, Przepiorka D, Tarrant J, Chan KW, Champlin R, Lichtiger B (1998) Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogenic marrow transplant recipients. Bone Marrow Transpl 22:575\u2013577","journal-title":"Bone Marrow Transpl"},{"key":"2661_CR142","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(89)92330-1","volume":"339","author":"GL Gilbert","year":"1989","unstructured":"Gilbert GL, Hudson IL, Hayes K, James J (1989) Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. Lancet 339:1228\u20131231","journal-title":"Lancet"},{"key":"2661_CR143","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1182\/blood.V97.11.3640","volume":"97","author":"LJ Dumont","year":"2001","unstructured":"Dumont LJ, Luka J, Van den Broeke T, Whitley P, Ambruso DR, Elfath MD (2001) The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood 97:3640\u20133647","journal-title":"Blood"},{"key":"2661_CR144","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/00365540110080412","volume":"34","author":"P Ljungman","year":"2002","unstructured":"Ljungman P, Larsson K, Kumlien G et al (2002) Leukocyte depleted unscreened blood products give al low risk for CMV infection and disease in CMV seronegative allogenic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis 34:347\u2013350","journal-title":"Scand J Infect Dis"},{"key":"2661_CR145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.bmt.1705090","volume":"36","author":"AB Narvios","year":"2005","unstructured":"Narvios AB, de Lima M, Shah H, Lichtiger B (2005) Transfusion of leucoreduced cellular blood components from cytomegalovirus-unscreened donors in allogenic hematopoietic transplant recipients: analysis of 72 recipients. Bone Marrow Transpl 36:499\u2013501","journal-title":"Bone Marrow Transpl"},{"key":"2661_CR146","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1046\/j.1537-2995.2001.41040560.x","volume":"41","author":"A Laupacis","year":"2001","unstructured":"Laupacis A, Brown J, Costello B et al (2001) Prevention of posttransfusion CMV in the era of universal WBC reduction: A consensus statement. Transfusion 41:560\u2013569","journal-title":"Transfusion"},{"key":"2661_CR147","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1046\/j.1537-2995.2000.40050500.x","volume":"40","author":"JD Roback","year":"2000","unstructured":"Roback JD, Bray RA, Hillyer CD (2000) Longitudinal monitoring of WBC subsets in packed RBC units after filtration: Implications for transfusion transmission of infections. Transfusion 40:500\u2013506","journal-title":"Transfusion"},{"key":"2661_CR148","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/j.1537-2995.2006.00926.x","volume":"46","author":"V Jayarama","year":"2006","unstructured":"Jayarama V, Marcello J, Olhagen A et al (2006) Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents. Transfusion 46:1580\u20131588","journal-title":"Transfusion"},{"key":"2661_CR149","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1537-2995.2004.03351.x","volume":"44","author":"CT Jordan","year":"2004","unstructured":"Jordan CT, Saakadze N, Newman JL et al (2004) Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion 44:1159\u20131165","journal-title":"Transfusion"},{"key":"2661_CR150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1423-0410.2012.01662.x","volume":"104","author":"CV Prowse","year":"2013","unstructured":"Prowse CV (2013) Component pathogen inactivation: a critical review. Vox Sang 104:183\u2013199","journal-title":"Vox Sang"},{"key":"2661_CR151","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.0041-1132.2005.04316.x","volume":"45","author":"L Lin","year":"2005","unstructured":"Lin L, Hanson CV, Alter HJ et al (2005) Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 45:580\u2013590","journal-title":"Transfusion"},{"key":"2661_CR152","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1423-0410.2010.01386.x","volume":"100","author":"SJ Wagner","year":"2011","unstructured":"Wagner SJ (2011) Developing pathogen reduction technologies for RBC suspensions. Vox Sang 100:112\u2013121","journal-title":"Vox Sang"},{"key":"2661_CR153","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/trf.12545","volume":"54","author":"KM Winter","year":"2014","unstructured":"Winter KM, Johnson L, Kwok M et al (2014) Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion 54:1798\u20131807","journal-title":"Transfusion"},{"key":"2661_CR154","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2014.07.005","volume":"28","author":"J Kaiser-Guignard","year":"2014","unstructured":"Kaiser-Guignard J, Canellini G, Lion N, Abonnenc M, Osselaer JC, Tissot JD (2014) The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 28:235\u2013241","journal-title":"Blood Rev"},{"key":"2661_CR155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000365646","volume":"41","author":"P Schlenke","year":"2014","unstructured":"Schlenke P (2014) Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 41:309\u2013325","journal-title":"Transfus Med Hemother"},{"key":"2661_CR156","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/trf.13030","volume":"55","author":"SD Keil","year":"2015","unstructured":"Keil SD, Bengrine A, Bowen R et al (2015) Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 55:1736\u20131744","journal-title":"Transfusion"},{"key":"2661_CR157","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/vox.12158","volume":"107","author":"SY Kwon","year":"2014","unstructured":"Kwon SY, Kim IS, Bae JE et al (2014) Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 107:254\u2013260","journal-title":"Vox Sang"},{"key":"2661_CR158","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.transci.2014.12.016","volume":"52","author":"V Salunkhe","year":"2015","unstructured":"Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Guti\u00e9rrez L (2015) Development of blood transfusion product pathogen reduction treatments: A review of methods, current applications and demands. Transfus Apher Sci 52:19\u201334","journal-title":"Transfus Apher Sci"},{"key":"2661_CR159","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tmrv.2014.02.002","volume":"28","author":"M Prudent","year":"2014","unstructured":"Prudent M, D'Alessandro A, Cazenave JP et al (2014) Proteome changes in platelets after pathogen inactivation -an interlaboratory consensus. Transfus Med Rev 28:72\u201383","journal-title":"Transfus Med Rev"},{"issue":"3","key":"2661_CR160","first-page":"CD009072","volume":"28","author":"C Butler","year":"2013","unstructured":"Butler C, Doree C, Estcourt LJ et al (2013) Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 28(3):CD9072","journal-title":"Cochrane Database Syst Rev"},{"key":"2661_CR161","unstructured":"CPMP\/BWP\/268\/95: Note for guidance on virus validation studies: design, contribution and interpretation of studies validating the inactivation and removal of viruses. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003684.pdf Zugegriffen: 31. Juli 2017"},{"key":"2661_CR162","unstructured":"EMA\/CHMP\/BWP\/706271\/2010: Guideline on plasma derived medicinal products. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/07\/WC500109627.pdf Zugegriffen: 31. Juli 2017"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-017-2661-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00103-017-2661-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-017-2661-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T03:48:10Z","timestamp":1719719290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00103-017-2661-3"}},"subtitle":["Stellungnahmen des Arbeitskreises Blut des Bundesministeriums f\u00fcr Gesundheit"],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":162,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["2661"],"URL":"https:\/\/doi.org\/10.1007\/s00103-017-2661-3","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,27]]}}}